Ipilimumab or the gp100 Vaccine or the Combination of Both as Therapy for Patients with Metastatic Melanoma

5-Minute Journal Club — ASCO 2010 Presentations

5-Minute Journal Club — ASCO 2010 Presentations

Bevacizumab in the Primary Treatment of Advanced Ovarian, Peritoneal or Fallopian Tube Carcinoma

AMG 386, an Angiogenesis Inhibitor, in the Treatment of Recurrent Ovarian, Peritoneal or Fallopian Tube Carcinoma

Correlation of BRCA Mutation Status with Responses to Platinum Therapy and PARP Inhibitors in Patients with Ovarian Cancer and Triple-Negative Breast Cancer (TNBC)

Bevacizumab in the Primary Treatment of Advanced Ovarian, Peritoneal or Fallopian Tube Carcinoma

5MJC Multimumor A

Pellentesque urna enim, mattis nec rhoncus eget, pharetra mattis quam. Phasellus nibh nibh, aliquet sit amet molestie eget

Year in Review – Multiple Myeloma: 2009-2010

Year in Review – Multiple Myeloma: 2009-2010

Consensus or Controversy, Issue 7: Clinical Assays to Assist in the Management of Breast Cancer

Consensus or Controversy, Issue 6: Therapy in Locally Advanced and Metastatic Disease

Consensus or Controversy, Issue 5: New Treatment and Biology Paradigms in Triple-Negative Breast Cancer (TNBC)

Consensus or Controversy, Issue 4: Practical Decisions Related to the Anti-Angiogenic Treatment of Breast Cancer

Consensus or Controversy, Issue 3: Common Adjuvant Scenarios

Consensus or Controversy, Issue 2: Endocrine Therapy; Bone Target Therapy

Syndicate content